Journal
CLINICAL NUCLEAR MEDICINE
Volume 45, Issue 1, Pages 92-93Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/RLU.0000000000002849
Keywords
FDG PET; hepatocellular carcinoma; hyperprogression; immunotherapy
Funding
- National Natural Science Foundation of China [81571713]
- Capital's Funds for Health Improvement and Research [2016-2-40115]
- CAMS Innovation Fund for Medical Sciences [2016-I2M-4-003, 2018I2M-3-001]
Ask authors/readers for more resources
Although immunotherapy is a successful approach in oncology, it might be detrimental to some patients. In the condition of hyperprogression, patients experience accelerated progression after immunotherapy, resulting in a worse outcome. Hyperprogression may be difficult to be identified in the early stage. Once the diagnosis is confirmed in the follow-up evaluation, the immunotherapy should be stopped immediately. In this case, we report a hyperprogression patient during combined immunotherapy toward metastatic hepatocellular carcinoma observed by serial F-18-FDG PET.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available